Comparative Pharmacology
Head-to-head clinical analysis: DIOVAN HCT versus METATENSIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIOVAN HCT versus METATENSIN 2.
DIOVAN HCT vs METATENSIN #2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, causing vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
METATENSIN #2 contains reserpine and methyclothiazide. Reserpine inhibits vesicular monoamine transporter (VMAT), depleting catecholamines from peripheral neurons. Methyclothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing fluid volume.
One tablet orally once daily. Available strengths: 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, 320 mg/25 mg. Titrate to blood pressure response; maximum dose 320 mg/25 mg daily.
1-2 tablets orally every 12 hours; each tablet contains reserpine 0.1 mg, hydralazine 25 mg, hydrochlorothiazide 15 mg.
None Documented
None Documented
Valsartan: 6 hours; hydrochlorothiazide: 6–15 hours (mean 9.6 hours). Clinical context: allows once-daily dosing; half-life prolonged in renal impairment.
12 hours (terminal); clinical context: twice-daily dosing maintains stable plasma levels
Valsartan: primarily biliary (83%) and renal (13%) as unchanged drug; hydrochlorothiazide: renal (≥95%) as unchanged drug.
Renal (80% unchanged, 15% as glucuronide metabolite); biliary/fecal (5%)
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination